Browsing by author "Banerji, Udai"
Now showing items 21-40 of 74
-
Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions.
Puglisi, M; Stewart, A; Thavasu, P; Frow, M; Carreira, S; et al. (KARGER, 2016-01-01)OBJECTIVES: We hypothesised that it was possible to quantify phosphorylation of important nodes in the phosphatidylinositol 3-kinase (PI3K) pathway in cancer cells isolated from pleural effusions of patients with non-small ... -
Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.
George, A; Kristeleit, R; Rafii, S; Michie, CO; Bowen, R; et al. (ELSEVIER SCI LTD, 2017-05-01)Drug resistance to conventional anticancer therapies is almost inevitable in patients with advanced ovarian cancer (AOC), limiting their available treatment options. Novel phase I trial therapies within a dedicated drug ... -
Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit.
Sundar, R; Custodio, A; Petruckevich, A; Chénard-Poirier, M; Ameratunga, M; et al. (ELSEVIER SCIENCE LONDON, 2018-03-01)AIMS: Advanced biliary tract carcinomas (ABC) are malignancies with limited effective therapies for advanced disease. There is little published evidence of outcomes of ABC patients participating in phase I clinical trials. ... -
Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit.
Papadatos-Pastos, D; Roda, D; De Miguel Luken, MJ; Petruckevitch, A; Jalil, A; et al. (ELSEVIER SCI LTD, 2017-04-01)BACKGROUND: We have previously reported a prognostic score for patients in phase I trials in the Drug Development Unit, treated at the Royal Marsden Hospital (RPS). The RPS is an objective tool used in patient selection ... -
Clinical trial designs for evaluating and exploiting cancer evolution.
Ingles Garces, AH; Porta, N; Graham, TA; Banerji, U (ELSEVIER SCI LTD, 2023-07-01)The evolution of drug-resistant cell subpopulations causes cancer treatment failure. Current preclinical evidence shows that it is possible to model herding of clonal evolution and collateral sensitivity where an initial ... -
Combine and conquer: challenges for targeted therapy combinations in early phase trials.
Lopez, JS; Banerji, U (NATURE PUBLISHING GROUP, 2017-01-01)Our increasing understanding of cancer biology has led to the development of molecularly targeted anticancer drugs. The full potential of these agents has not, however, been realised, owing to the presence of de novo ... -
Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials.
Geuna, E; Roda, D; Rafii, S; Jimenez, B; Capelan, M; et al. (NATURE PUBLISHING GROUP, 2015-12-01)BACKGROUND: PI3K-AKT-mTOR inhibitors (PAMi) are promising anticancer treatments. Hyperglycaemia is a mechanism-based toxicity of these agents and is becoming increasingly important with their use in larger numbers of ... -
Critical parameters in targeted drug development: the pharmacological audit trail.
Banerji, U; Workman, P (W B SAUNDERS CO-ELSEVIER INC, 2016-08-01)The Pharmacological Audit Trail (PhAT) comprises a set of critical questions that need to be asked during discovery and development of an anticancer drug. Key aspects include: (1) defining a patient population; (2) ... -
Development and validation of a LC-MS/MS method for the quantification of the checkpoint kinase 1 inhibitor SRA737 in human plasma.
Zangarini, M; Berry, P; Sludden, J; Raynaud, FI; Banerji, U; et al. (FUTURE SCI LTD, 2017-07-01)AIM: SRA737 is an orally active small-molecule inhibitor of checkpoint kinase 1 being investigated in an oncology setting. A HPLC-MS/MS method for quantifying plasma concentrations of SRA737 was validated. METHODS & RESULTS: ... -
Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers.
Stewart, A; Coker, EA; Pölsterl, S; Georgiou, A; Minchom, AR; et al. (AMER ASSOC CANCER RESEARCH, 2019-08-01)It is increasingly appreciated that drug response to different cancers driven by the same oncogene is different and may relate to differences in rewiring of signal transduction. We aimed to study differences in dynamic ... -
Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation.
Dillon, MT; Guevara, J; Mohammed, K; Patin, EC; Smith, SA; et al. (AMER SOC CLINICAL INVESTIGATION INC, 2024-01-16)BACKGROUNDPhase 1 study of ATRinhibition alone or with radiation therapy (PATRIOT) was a first-in-human phase I study of the oral ATR (ataxia telangiectasia and Rad3-related) inhibitor ceralasertib (AZD6738) in advanced ... -
Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial.
Banerjee, S; Giannone, G; Clamp, AR; Ennis, DP; Glasspool, RM; et al. (AMER MEDICAL ASSOC, 2023-05-01)IMPORTANCE: Patients with platinum-resistant or refractory ovarian high-grade serous carcinoma (PR-HGSC) have a poor prognosis and few therapeutic options. Preclinical studies support targeting PI3K/AKT/mTOR signaling in ... -
Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models.
Wong Te Fong, A-C; Thavasu, P; Gagrica, S; Swales, KE; Leach, MO; et al. (IMPACT JOURNALS LLC, 2017-12-26)Activation of the PI3K/mTOR pathway has been shown to be correlated with resistance to chemotherapy in ovarian cancer. We aimed to investigate the effects of combining inhibition of mTORC1 and 2 using the mTOR kinase ... -
Exploiting evolutionary steering to induce collateral drug sensitivity in cancer.
Acar, A; Nichol, D; Fernandez-Mateos, J; Cresswell, GD; Barozzi, I; et al. (NATURE PORTFOLIO, 2020-04-21)Drug resistance mediated by clonal evolution is arguably the biggest problem in cancer therapy today. However, evolving resistance to one drug may come at a cost of decreased fecundity or increased sensitivity to another ... -
First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.
Basu, B; Dean, E; Puglisi, M; Greystoke, A; Ong, M; et al. (AMER ASSOC CANCER RESEARCH, 2015-08-01)PURPOSE: AZD2014 is a novel, oral, m-TORC 1/2 inhibitor that has shown in vitro and in vivo efficacy across a range of preclinical human cancer models. EXPERIMENTAL DESIGN: A rolling six-dose escalation was performed to ... -
First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors.
Shimomura, A; Yamamoto, N; Kondo, S; Fujiwara, Y; Suzuki, S; et al. (AMER ASSOC CANCER RESEARCH, 2019-03-01)HSP90 is involved in stability and function of cancer-related proteins. This study was conducted to define the MTD, safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor efficacy of TAS-116, a novel class, ... -
First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors.
McLeod, R; Kumar, R; Papadatos-Pastos, D; Mateo, J; Brown, JS; et al. (AMER ASSOC CANCER RESEARCH, 2020-09-15)PURPOSE: AT13148 is an oral AGC kinase inhibitor, which potently inhibits ROCK and AKT kinases. In preclinical models, AT13148 has been shown to have antimetastatic and antiproliferative activity. PATIENTS AND METHODS: The ... -
HER3 expression and MEK activation in non-small-cell lung carcinoma.
Manickavasagar, T; Yuan, W; Carreira, S; Gurel, B; Miranda, S; et al. (FUTURE MEDICINE LTD, 2021-04-09)AIM: We explore HER3 expression in lung adenocarcinoma (adeno-NSCLC) and identify potential mechanisms of HER3 expression. MATERIALS & METHODS: Tumor samples from 45 patients with adeno-NSCLC were analyzed. HER3 and HER2 ... -
Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials.
Rafii, S; Roda, D; Geuna, E; Jimenez, B; Rihawi, K; et al. (AMER ASSOC CANCER RESEARCH, 2015-04-15)PURPOSE: Novel antitumor therapies against the PI3K-AKT-mTOR pathway are increasingly used to treat cancer, either as single agents or in combination with chemotherapy or other targeted therapies. Although these agents are ... -
Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management.
Khan, KH; Wong, M; Rihawi, K; Bodla, S; Morganstein, D; et al. (ALPHAMED PRESS, 2016-07-01)BACKGROUND: Dysregulation of the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway is implicated in human cancer growth and progression. Agents targeting this pathway are ...